Artificial tears contamination risk

Article

Multiple-use packs of preservative-free artificial tears are susceptible to contamination, according to study results published in the November issue of the British Journal of Ophthalmology.

Multiple-use packs of preservative-free artificial tears are susceptible to contamination, according to study results published in the November issue of the British Journal of Ophthalmology.

Dr C Y Choi of the Department of Ophthalmology at Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, 108, Pyeongdong, Jongnogu, Seoul, Republic of Korea and colleagues cultured the fluid remaining in multiple-use bottles (n=242) of both preservative-free and preservative-containing artificial tears after ≥3 administrations per 10 hours.

The team found microbial contamination in 2.0% of the bottles (n=5). All contaminations were found in bottles containing the preservative-free tears, and were either coagulase-negative staphylococcus or gram-negative acinetobacter. After multivariate regression analysis it emerged that age and fingertip touch were the factors with the greatest influence on contamination rates.

The researchers concluded that resealable packs of preservative-free artificial tears, especially when used by older patients and/or when fingertip touch was significant, are prone to infection in daily and multiple use settings.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.